NCT01343173 (STIM 2) is a NA clinical trial of Imatinib stop in Chronic Myeloid Leukaemia, sponsored by University Hospital, Bordeaux.

Who is sponsoring NCT01343173?

NCT01343173 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT01343173?

Interventions in NCT01343173: Imatinib stop.

What condition does NCT01343173 study?

NCT01343173 studies Chronic Myeloid Leukaemia.

Is NCT01343173 still recruiting?

NCT01343173 is currently completed. Last updated 13 March 2018.

Last reviewed 2018-03-13 · How we verify

NCT01343173: STIM 2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib

Completed NA Last updated 13 March 2018

What this trial tests

NA trial testing Imatinib stop in Chronic Myeloid Leukaemia in 220 participants. Completed in 30 May 2017.

Timeline

6 April 2011

Primary endpoint
30 May 2017

30 May 2017

Quick facts

Lead sponsor	University Hospital, Bordeaux
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	220
Start date	6 April 2011
Primary completion	30 May 2017
Estimated completion	30 May 2017
Sites	32 locations across France

Drugs / interventions tested

Imatinib stop — full drug profile →

Conditions studied

Chronic Myeloid Leukaemia — all drugs for Chronic Myeloid Leukaemia →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Chronic Myeloid Leukaemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Complete molecular remission under imatinib, therapeutic interruption possible for patients in complete remission proved in different trials. Purpose: Stopping imatinib in patients with chronic myeloid leukemia in complete molecular remission during two following years. The objectives of this study are to determine the rate of patients without a molecular relapse and so the rate of molecular relapse, to determine and to seek for clinical and biological CML-related factors predictive for a molecular relapse after imatinib discontinuation. These objectives require to increase the number of study patients to be enrolled for accurate statistical considerations. It will allow to predict which patients have to be proposed for discontinuation without risk of molecular relapse and to select the patients who need to continue or reinforce the treatment to achieve a complete long term eradication of the disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY, Bérard E, Bréal C, Dulucq S, et al · · 2019 · cited 12× · PMID 31287239 · DOI 10.1002/cam4.2371

Verify or expand the search:

Other recruiting trials for Chronic Myeloid Leukaemia

Currently open trials in the same condition.

NCT05682924 — Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01343173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 13 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01343173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing